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IntroductIon
An integral part of the pharmaceutical research drug discovery process is the transformation of hit or lead 
structures into drugable development candidates. Beside activity 
and selectivity, the major optimization driving force for early 
stage research projects are in vitro absorption, distribution, metab-
olism, excretion (aDme) properties. Data derived from key 
aDme assays such as cYp450 inhibition, metabolic stability, 
and permeability (caco-2 and parallel artificial membrane perme-
ability assay [pampa]) provide elementary and decisive infor-
mation on the drug-drug interaction (DDi) potential, metabolic 
behavior, and intestinal absorption of the drug candidate com-
pounds. streamlining the aDme assessments is a major task for 
research scientists dedicated to early drug discovery support to 
enable a timely delivery of data. over the past years, increasing 
analytical capacity often has simply been a matter of purchasing 
additional liquid chromatography/tandem mass spectrometry 
(lc/ms/ms) systems. fast analytical approaches speeding up 
the analytical process such as ultra-performance liquid chroma-
tography (uplc),1 the application of short or monolithic col-
umns,2 pooling samples,3 multiplexed approaches,4,5 and the use 
of new interfaces to mass spectrometers6,7 aim at overcoming the 
bottleneck of huge sample load versus speed and short cycle 
times. in addition to the hardware aspect, commercially available 
mass spectrometric system software usually is not easy to inte-
grate into established workflows. therefore, existing analytical 
systems do not offer a flexible and automated analytical platform 
combined with adequate speed. common mass spectrometric 
automation software usually is programmed to run one assay with 
different analytes but not different assays with different analytes. 
Both hardware speed and integration of the system into the daily 
workflow are essential components of an effective high-throughput 
lc/ms/ms system. the establishment of exactly harmonized 
interfaces between the experimental and the analytical part, such 
as barcode-labeled analysis plates with enclosed file information, 
was often neglected. it was obvious that effectiveness could be 
improved by introducing standardized formats for assays, provid-
ing information on assay projects electronically and keeping 
processes as simple as possible.
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over the past decade, drug discovery programs have started to address the optimization of key aDme properties already at 
an early stage of the process. hence, analytical chemists have been confronted with tremendously rising sample numbers and 
have had to develop methodologies accelerating quantitative liquid chromatography/tandem mass spectrometry (lc/ms/
ms). this article focuses on the application of a generic and fully automated lc/ms/ms, named rapid and integrated 
analysis system (rias), as a high-throughput platform for the rapid quantification of drug-like compounds in various in 
vitro aDme assays. previous efforts were dedicated to the setup and feasibility study of a workflow-integrated platform 
combining a modified high-throughput liquid handling lc/ms/ms system controlled by a customized software interface and 
a customized data-processing and reporting tool. herein the authors present an extension of this previously developed basic 
application to a broad set of aDme screening campaigns, covering cYp inhibition, caco-2, and pampa assays. the plat-
form is capable of switching automatically between various aDme assays, performs ms compound optimization if required, 
and provides a speed of 8 s from sample to sample, independently of the type of aDme assay. Quantification and peak 
review are adopted to the high-throughput environment and tested against a standard hplc-esi technology. (Journal of 
Biomolecular Screening 2011;16:370-377)
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regarding the analytical part, software tools for ms com-
pound optimization and data processing8-10 were developed to 
facilitate and speed up analytical processes. although the above-
mentioned approaches such as uplc1 or new interfaces6,7 
already speed up sample analysis, both the autosampler and lc 
part are still the rate-limiting factor of lc/ms/ms analysis. 
modern triple quadrupole mass spectrometers have scan speeds 
in the low millisecond range, resulting in the reliable acquisition 
of narrow peaks with a reasonable number of data points for 
qualitative and quantitative analysis. nevertheless, most of the 
analysis time is spent acquiring noise (e.g., data before and after 
the peaks of interest have occurred in the mass spectrometer). 
the rapidfire autosampling technology applied in the rapid 
and integrated analysis system provides narrow and fast con-
secutive peaks and, therefore, in combination with a mass spec-
trometer accentuates the excellence of triple quadrupole mass 
spectrometry: high sensitivity combined with high selectivity. 
many of the above-mentioned approaches provide narrow peaks 
and analysis times far below 1 minute.2,5,11 for our applications, 
a generic high-throughput lc/ms/ms system capable of run-
ning different aDme assays and performing compound optimi-
zation as well as sample measurement in a highly automated way 
was desirable. We herein present such a solution: a fully auto-
mated and universal in vitro aDme platform termed RIAS 
(rapid and integrated analysis system) that is easy to use, 
secure in data handling, and capable of analyzing up to 450 sam-
ples per hour. examples are shown for different types of aDme 
assays, which are known as standard investigations in early drug 
metabolism pharmacokinetics (DmpK): cytochrome p450 inhi-
bition (cYp), caco-2 cell permeability (prm), and pampa 
(abbr. pmp).
the herein presented rias enables quantitative high-
throughput mass spectrometry as a secure, easy to use setup for 
a broad community working in the field of aDme. it may pro-
vide new opportunities for quantitative mass spectrometry in 
fields that either were not accessible until now or have been 
neglected because of lack of sufficient throughput (e.g., high-
throughput screening [hts] campaigns).
ExPErIMEntAL
Reagents
acetonitrile (gradient grade) was acquired from merck 
(Darmstadt, germany), methanol (gradient grade) from J. t. Baker 
(Deventer, netherlands), and formic acid (p.a.) and trifluoroacetic 
acid (tfa, reagent grade) from sigma aldrich (st. louis, mo). 
ammonium acetate (p.a.) and ammonia solution (25%, p.a.) were 
purchased from merck. Water was prepared in-house by a purifi-
cation system (elgastat maxima hplc, elga ltd., high Wycombe 
Bucks, uK). the cYp450 test compounds benzbromarone, fluox-
etine, norfluoxetine, paroxetine, sulfaphenazole, ticlopidine, amo-
diaquine, 1-hydroxymidazolam, dextromethorphan, dextrorphan, 
diclofenac, 4-hydroxydiclofenac, 4-hydroxymephenytoin, and 
erythromycin were purchased from sigma aldrich; 13c6-4-
hydroxydiclofenac, S-mephenytoin, 2h3-4-hydroxymephenytoin, 
and 2h6-dehydronifedipine were purchased from toronto research 
chemicals (ontario, canada). 2h3-dextrorphan and 
2h5-
desethylamodiaquine were obtained from cerilliant corporation 
(round rock, tX), ketoconazole was purchased from tocris 
Bioscience (Bristol, uK), and midazolam was purchased from 
roche pharma ag (grenzach-Wyhlen, germany). the residual 
112 proprietary compounds were synthesized in-house at 
Boehringer ingelheim pharma gmbh & co Kg (Bi, Biberach, 
germany). overall, the compounds were within a molecular mass 
range of 250 and 800 Da, and calculated logp values (acD/labs, 
version 11; acD, inc., toronto, canada) were in the range 
between –2.5 and 7. the rapidfire cartridges were purchased 
from Biocius (Woburn, ma), the 0.8-ml 96-well plates and the 
“easy peel” sealing mats were obtained from thermo scientific 
(hamburg, germany).
Cytochrome P450 assay
the inhibition of cytochrome p450–catalyzed metabolism of 
a specific substrate to the respective analyte was assayed at 
37 ° c with human liver microsomes. all assays were carried out 
on a robotic system in 96-well plates. the final incubation con-
tained tris buffer (0.1 m), mgcl2 (5 mm), cofactor (nicotina-
mide adenine dinucleotide phosphate [naDph], 1 mm), human 
liver microsomes, the specific substrate, and the test compound 
at a concentration range of 0–50 µm. reactions were terminated 
by cooling the incubation down to 8  °c and subsequently by 
adding one volume of acetonitrile for protein precipitation. an 
internal standard solution—usually a stably labeled isotope of 
the substrate product—was added afterwards. the peak areas of 
the product (p) and of the internal standard (is) were determined 
by lc/ms/ms. the resulting peak area ratio of product to inter-
nal standard (p:is) was used to calculate ic50s. the ms and 
incubation conditions are summarized in table 1.
Caco-2 assay
a 10-µm test compound solution in assay buffer (ph 7.4) 
was added to the donor compartment of the caco-2 cell cham-
ber. after predefined intervals (up to 90 min), samples were 
drawn from the receiver and donor compartment, respectively. 
for analysis in the rias, samples from the donor compartment 
were diluted 1:50 (v:v), and an aliquot of a proprietary internal 
standard was added to all samples.
PAMPA assay
the pampa assay was performed at ph 5, ph 6.5, and 
ph 7.4, resembling the environment in different intestinal sections. 
the donor concentration was very high (target concentration 
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200 µm, filtration prior to incubation) to also allow analysis of 
poorly permeable compounds. samples therefore had to be 
diluted 1:50 (v:v) with meoh/water (50:50; v:v) for donor sam-
ples and 1:3 (v:v) for samples from the receiver compartment, 
respectively. the sample preparation and raw data analysis fol-
lowed the procedure of the above-described caco-2 assay.
samples from all assays described were provided in 96-well 
format and centrifuged prior to analysis in the rias for 10 min 
at 4000 rpm and 4  °c (multifuge 3sr+, thermoscientific, 
osterode, germany).
InStruMEntAtIon
the original rapidfire system12 was customized to a fully 
automated and flexible platform, termed rias. in this modi-
fied setup, the sample was aspirated by a vacuum pump into a 
10-µl sample loop for 250 ms and flushed onto a c4 cartridge 
(3.8 µl bed volume; Biocius) with the aqueous mobile phase 
(99.9% water, 0.09% formic acid, and 0.01% tfa; flow rate 
1.5 ml/min). a solid-phase extraction step retained the analyte 
for 3000 ms while interfering matrix (e.g., buffer components) 
was removed. With a simple step gradient, the analyte was 
back-eluted from the cartridge for 3000 ms with the organic 
mobile phase (99.9% acetonitrile/methanol [1:1, v:v], 0.09% 
formic acid, and 0.01% tfa) and flushed into the mass spec-
trometer at a flow rate of 1.25 ml/min. afterwards, the car-
tridge was reequilibrated with the aqueous mobile phase for 
500 ms (flow rate 1.5 ml/min). a detailed description of the 
hardware setup was provided previously.13,14 the rapidfire and 
a customized control software were obtained from Biocius. 
QuickQuan 2.3, Xcalibur 2.0.7, and XDK 2.1.0.25 were used 
to operate the tsQ Vantage (thermofisher, san Jose, ca). 
mass spectral data-processing software Quickcalc 7.1.9 was 
purchased from thermofisher. the master software for the 
rias was programmed in-house using labVieW (version 
8.6.1; national instruments, austin, tX). Data analysis was 
performed in assayexplorer 3.2 (symyx, sunnyvale, ca), and 
correlation plots were visualized in spotfire version 2.2.0 
(tiBco, palo alto, ca).
rESuLtS And dIScuSSIon
the rias has been established previously to automatically 
perform fast and robust lc/ms/ms analysis of metabolic sta-
bility samples.13,14 in this contribution, we extend and demon-
strate the applicability of the automated system to further key 
aDme assays such as caco-2, pampa, and cYp, including 
assay type recognition and ms compound optimization.
System setup development
the central turntable for operations of the rias constitutes 
the in-house programmed labVieW software (fig. 1). Both 
the modified rapidfire and the triple quadrupole mass spec-
trometer are controlled according to handshake principles. 
thus, operations of the rias are timed and triggered via the 
labVieW software. in most of the aDme assays, the research 
compound itself has to be quantified, which adds a level of 
complexity to the entire process. the customized rapidfire 
and the mass spectrometer can be set to compound optimiza-
tion (tuning) or analysis mode measurement sequences submit-
ted via software commands. Key for an automated analytical 
workflow and high level of automation of the system is the 
barcode-mediated differentiation into different types of plates, 
depending on the purpose (sample or tuning) and the assay type 
(cYp, caco-2, pampa, metabolic stability). this was realized 
by the implementation of naming rules, which resulted in 
“speaking” acronyms in the plate barcode. a distinction 
table 1. mass spectrometry and incubation conditions for cYp450 inhibition reactions
CYP Substrate (Abbreviation)
Metabolite (Met)  
MRM Q1>Q3, amu
Internal Standard 
(IS) MRMQ1>Q3, 
amu
Ionization 
Mode
S-Lense Met/
IS, V
CE Met/ 
IS, V
Substrate 
Concentration, 
µM
Protein Content, 
mg/mL
p450 3a4 midazolam (mDZ) 1-oh-mDZ D4-1-oh-mDZ positive 68/80 26/26  5 0.1
 342.1>203.1 346.1>203.1  
p450 3a4 erythromycin (erY) n-Desethyl-erY D6-ox-nifedipine positive 92/106 40/35 50 0.5
 720.4>144.0 351.1>287.1  
p450 2D6 Dextromethorphan (DeX) Dextrorphan
258.2>157.1
D3-Dextrorphan
261.2>157.2
positive 70/68 37/37  5 0.2
p450 2c8 amodiaquine (amo) Desethyl-amo
328.2>283.2
D5-Desethyl-amo
333.2>283.2
positive 61/61 19/19  1 0.05
p450 2c9 Diclofenac (Dic) 4-oh-Dic 13c6-4-oh-Dic positive 52/79 19/19 10 0.5
 312.1>231.2 318.0>237.2  
p450 2c19 mephenytoin (meph) 4-oh-meph D3-4-oh-meph negative 42/61 16/16 70 0.5
 233.3>190.3 236.3>193.3  
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between plates by the system is mandatory for the use of pre-
defined injection series depending on purpose and assay type. 
in addition, this guarantees an unattended operation over many 
plates from different assays for both tuning and sample meas-
urement. in summary, the automated differentiation of assay 
formats (cYp, prm, pmp, metabolic stability [mst]) as well 
as of sample types (tuning, sample) was achieved via barcode-
labeled plates triggering specific actions within the system 
(“active barcoding”).
an important task of the operating system is to distinguish 
whether a compound optimization is necessary for a specific assay. 
in this regard, samples from the cYp450 inhibition assay require 
the measurement of product analytes generated by metabolism of 
specific substrates. Because the formed product analytes are 
known and monitored independently of the research compounds, 
ms measurement parameters and methods have been established 
and stored in QuickQuan’s database to be instantly retrieved if 
necessary (table 1). in contrast, all other above-mentioned assays 
(prm, pmp, and mst) require the direct measurement and 
quantification of the investigated compounds themselves and 
require, therefore, compound optimization by means of tuning 
plates. hence, when a compound has been optimized, future ana-
lytics of this compound does not require a new optimization proc-
ess. if a compound under investigation has already been tuned 
before, the rias will skip the tuning procedure. in case the rias 
contains loaded samples of compounds without tuning informa-
tion in the database, the system will skip the processing and save 
these samples until the tuning plate of these compounds has been 
processed. compound optimization with the rias was performed 
with pure compound solutions (concentration 1 µm) using the 
rapidfire setup with subtle differences regarding elution flow rate 
and valve switching times. hence, time for the solid-phase extrac-
tion step from the rapidfire system was reduced from 3000 to 
1000 ms. next, the elution flow rate of the compound into the 
mass spectrometer was reduced to 0.3 ml/min to achieve a per-
sistent signal for the ms optimization procedure. timing of injec-
tions was triggered from the labVieW software upon request 
from the QuickQuan software. During the compound optimization 
“active barcoding”
T = tuning plates from
PRM,PMP
and MST T
T
T
T
S = sample plates from
CYP, PRM, PMP
and MSTS
S
S
S
Peak Review
(QuickCalcTM)
Data Analysis
(AssayExplorer TM)
RIAS
(LabVIEW)
Master Software
RapidFireTM
TSQ Vantage
(QuickQuanTM
& XcaliburTM)
Data Base
Data Reporting
(Spotfire®)
Server
∆ T & S plates and ∆ Assay Type 
fIg. 1. schematic data flow of the high-throughput rias (rapid and integrated analysis system): the rias master software represents the 
central turntable of the entire system. the software controls the interplay between the rapidfire injection module and the thermo tsQ Vantage 
ms. Based on the barcode label of the plates, the software recognizes plate type (tuning or sample) as well as assay type (cytochrome p450 
inhibition [cYp], caco-2 cell permeability [prm], parallel artificial membrane permeability [pmp], metabolic stability [mst]) and retrieves 
plate layout information, such as compound name, molecular formula, and selected internal standard. all of these steps trigger experiment- 
specific actions. the demonstrated data flow minimizes generation of large amounts of files by usage of databases.
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process, basic mass spectrometric parameters such as ionization 
polarity (positive or negative), s-lense, and ce-voltage as well as 
the multiple reaction monitoring (mrm) transition were auto-
matically determined and stored in the QuickQuan database. the 
optimization process was performed at ph 7.4 to facilitate com-
pound tuning for both positive and negative ionization mode. the 
aqueous phase for sample loading onto the c4 cartridge was 10 
mm ammonium acetate in water, and the organic solvent for the 
back elution into the mass spectrometer was 95% acetonitrile/
methanol (1:1, v:v) with 5% 10 mm ammonium acetate at ph 7.4. 
the success rate of the automated compound optimization proce-
dure with the rias was determined retrospectively for 331 differ-
ent compounds over several months and was found to be 98% 
(successful optimizations within 1.5 min/compound). all protocols 
from automated or manual optimization were routinely reviewed to 
check s-lense and ce-voltage ramps as well as survey scans and 
ms product ion spectra provided in the ms software optimization 
protocols. if the automated compound optimization procedure 
failed, conventional off-line infusion (flow rate 10 µl/min) of a 
1-µm compound solution was performed using Xcalibur’s internal 
tuning software. hence, by the implementation of “active barcod-
ing,” the rias is able to automatically perform plate differentiation 
and triggers operations of the system without manual interaction.
the starting point of the analytical workflow of the revised 
rias (cf. fig. 1) is the barcode reading of a plate by a scanner 
located next to the plate-handling device. scanning the barcode 
enables access to a specific plate identification file, which is 
provided on a server and contains plate specific analytical infor-
mation (e.g., compound name, molecular formula, unique identi-
fier, and internal standard). after ms optimization of analytes, the 
compound-specific information is stored in QuickQuan’s database 
and can be instantly retrieved if necessary during sample analysis 
by providing specific mrm conditions. labVieW software trig-
gers the acquisition mode in the QuickQuan software and initiates 
both ms method generation and submission of sequences for the 
analysis in the rias. Data acquisition is performed in high-
throughput (ht) mode with all samples from an assay series 
included in a single file5,11,14 to reduce the number of data files. the 
cycle time between injections of analytes is 8 s, regardless if sam-
ples originate from an mst assay, a cYp450 inhibition assay, or 
a permeability assay (pmp or prm). after data acquisition, ms 
raw data are moved to a network server for a quick peak review in 
the ht mode (fig. 2). processed data are stored in a database via 
Quickcalc and can be retrieved during data analysis for automated 
calculation of aDme parameters such as ic50, half-life (t1/2), or 
permeability coefficients (papp).
ADME assay use cases for the assessment of  
the RIAS performance
CYP450 inhibition (CYP). as depicted in figure 2, all sam-
ples of one inhibition experiment (16 samples, including blank 
and matrix injections) were analyzed within a run of 2.5 min. 
the individual samples were injected in the order of decreasing 
test compound concentrations (presumably leading to increas-
ing analyte concentration, if inhibition of the substrate reaction 
was concentration dependent) followed by a blank and the 
duplicate incubation samples. the upper panel represents the 
analyte mrm trace, whereas the lower panel shows the mrm 
trace of the stably labeled internal standard. an inhibition 
potential of a test compound can already be estimated during 
peak review on the screen.
samples from cYp inhibition experiments were analyzed 
on a validated lc/ms/ms setup as well as with the rias. 
eight representative drugs (benzbromarone, fluoxetine, ketoco-
nazole, norfluoxetine, paroxetine, propranolole, sulfaphena-
zole, ticlopidine) were each tested toward six different p450 
substrate reactions with midazolam, erythromycin, dextrometh-
orphan, amodiaquine, diclofenac, and mephenytoin, yielding 
48 cross-validation ic50 results (fig. 3A). the double-logarith-
mic cross-validation diagram displays ic50 values over the 
entire concentration range, including compounds with no or 
tolerable DDi (ic50 > 10 µm) and compounds with high DDi 
(ic50 < 1 µm). the correlation of quantitative data is excellent 
over the depicted concentration range (correlation coefficient 
r2 = 0.989).
Caco-2—permeability (PRM). samples from the daily labora-
tory routine that were already analyzed with the conventional 
ms system were selected for a reanalysis with the rias. figure 
3B depicts the double-logarithmic diagram displaying an excel-
lent correlation of permeability coefficients (papp,15 r2 = 0.969) 
of samples from 110 caco-2 experiments with different Bi pro-
prietary compounds measured on both systems. in the rias, ms 
compound optimization was automatically performed for all 
compounds. the time required for sample analysis was 8 s from 
sample to sample compared to 1 min per sample with the vali-
dated lc/ms/ms system. the caco-2 assay differentiates poorly 
permeable compounds (papp <5 × 10−7 cm/s; red line in fig. 
3B) as well as highly permeable compounds (papp >5 × 10−6 
cm/s; green line in fig. 3B). compounds with permeability coef-
ficients >5 × 10−7 cm/s but <5 × 10−6 cm/s are considered 
medium permeable in the caco-2 assay. the blue squares indi-
cate samples measured the same day, whereas the red squares 
indicate samples measured on the rias after (a timely delay 
and) one additional freeze-thaw cycle.
PAMPA—parallel artificial membrane permeation assay 
(PMP). a high correlation of rias–electrospray ionization 
(esi)–ms to hplc-esi-ms could also be demonstrated for 
the pampa assay. figure 3c depicts a high correlation (r2 = 
0.891) of papp15 between these systems. again, fully auto-
mated ms compound optimization on the rias was success-
ful. Bi proprietary compounds were investigated in 35 
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different experiments at ph 5 (red squares), ph 6.5 (blue 
squares), and ph 7.4 (green squares). most of the compounds 
showed high permeability in the assay (papp >1 × 10−7 cm/s; 
green line in fig. 3c), some medium permeability (>1 × 10−8 
but <1 × 10−7 cm/s), and a few low permeability (<1 × 10−8 
cm/s; red line in fig. 3c). the rias samples have been 
measured with a more sensitive triple quadrupole mass spec-
trometer compared to the validated system. a higher variabil-
ity observed for low-permeable compounds (<1 × 10−8 cm/s) 
was usually correlated to a lower limit of quantitation (lloQ). 
cycle time from sample to sample was 8 s compared to 1 min 
with the validated approach.
the rias is a universal analytical high-throughput platform 
for in vitro aDme key assays, easy to use, and secure in data 
handling. providing a high level of automation and a speed of 
8 s per sample, it enables the analyst to run up to 450 samples 
per hour from various aDme assays such as cYp450 inhibi-
tion, caco-2, pampa, or mst13,14 in real-life applications. 
time-consuming and tedious switching between compound 
optimization and sample measurement from various assays as 
well as data management in daily lc/ms/ms work was com-
pletely handled by the new unified platform without manual 
intervention. the setup of the rias for cYp450 inhibition 
enabled us to replace a laborious and cost-intensive radiometric 
fIg. 2. simplified data processing in high-throughput (ht) mode: the application of ht data acquisition and data processing simplifies and 
shortens the peak review as depicted from an example of a cYp450 inhibition experiment analysis. the inhibition of the formation of 
4-oh-mephenytoin (upper mrm transition) from mephenytoin in human liver microsomes in the presence of an inhibitor is displayed. each peak 
represents a single-point incubation with increasing amounts of a potential inhibitor followed by a blank and the subsequent duplicate incuba-
tions. inhibition of formation of the known metabolite leads to a reduced peak signal for 4-oh-mephenytoin and enables a compound-specific 
ic50 calculation for the isoenzyme. the mrm transition on the bottom depicts the stable labeled internal standard (
2h3-4-oh-mephenytoin), 
which was added after quenching the microsomal incubation. in this application, the ht data review enables a quick peak review and integration 
check of 17 injections stored into one chromatogram.
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inhibition assay, resulting in substantial savings with respect to 
time and money. the concept of “active barcoding” was introduced 
to our knowledge for the first time to lc/ms/ms analysis. 
conventional barcode applications use the barcode to generate 
a raw data acquisition file name from a plate identifier. in our 
case, this step is only one aspect of the entire active barcoding 
fIg. 3. (A) correlation of ic50 values from a validated liquid chromatography/tandem mass spectrometry (lc/ms/ms) system to the rapid 
and integrated analysis system (rias). eight drugs (benzbromarone, fluoxetine, ketoconazole, norfluoxetine, paroxetine, propranolole, sulfa-
phenazole, ticlopidine) were investigated for their inhibition potential (ic50) toward the isoenzymes cYp450 3a4 (substrates midazolam and 
erythromycin), 2c8 (amodiaquine), 2D6 (dextromethorphan), 2c9 (diclofenac), and 2c19 (mephenytoin). cycle time from sample to sample was 
8 s based on rapidfire technology compared to ~2.5 min with a conventional lc/ms/ms approach. (B) correlation of permeability coefficients 
(papp) 110 caco-2 experiments. correlation of papp derived from a validated lc/ms/ms system (x-axis) and the ht/ms/ms (y-axis) system 
rias. samples were generated from a caco-2 assay, which is a surrogate for the in vivo permeability of an orally administered compound. Blue 
squares indicate samples that had been measured the same day on the validated lc/ms/ms system and the rias, whereas red squares indicate 
a delay of at least one day and one additional freeze-thaw cycle prior to measurement on the rias. (c) correlation of papp of 35 parallel arti-
ficial membrane permeation assay (pampa) experiments. correlation of papp derived from samples from a pampa on a validated lc/ms/ms 
system (x-axis) and the rias (y-axis). all data were obtained after fully automated ms compound optimization on the rias. proprietary 
Boehringer ingelheim compounds were investigated at different ph values and display low (<1 × 10−8 cm/s), medium (>1 × 10−8 but <1 × 10−7 cm/s), 
or high permeability in the assay. cycle time from sample to sample is 8 s on the rias compared to 1 min with the validated approach.
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principle. Barcode reading is also linked to different kinds of 
system actions/procedures such as recognition of assay type, 
loading of injection templates, differentiation between sample 
and tuning plates, and initiation of both compound optimiza-
tion and sample measurement. only the complete integration 
enables an unattended operation of the rias and provides a 
general applicability to various types of assays with different 
setups in a high-throughput environment. the system is con-
trolled via a central master software and has been integrated 
into the workflow not only with the purpose to speed up but 
also to pass interfaces smoothly, to avoid copy/paste transac-
tions, and to allow the usage of databases as data exchange and 
transfer turntables. in our view, this is the first report on a sys-
tem that covers and unifies the analysis of samples from very 
different types of aDme assays at such an advanced level of 
automation and speed. We currently have limited the applica-
tion of the entire system to in vitro aDme. however, our cur-
rent efforts are directed to an extension toward the analysis of 
pharmacokinetic and toxicokinetic in vivo samples.14
We are aware that the rias represents an in-house custom-
ized solution of commercially available components from dif-
ferent vendors. this customization, however, is in accordance 
with some basic but mandatory rules that can be transferred to 
any other platform. first, it is important to integrate the system 
into a well-designed workflow philosophy where copy/paste 
actions of data information should be avoided and active bar-
coding should be established. furthermore, it is necessary to set 
up communication interfaces between single-system compo-
nents (i.e., mass spectrometer and autosampler). finally, for 
this kind of system, an automated ms compound optimization 
routine is required that enables automated storage and access of 
tuning information in and from a database.
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